[Comment] Establishing cardiovascular safety of the small-molecule GLP-1 receptor agonist orforglipron in type 2 diabetes
來源 柳叶刀 Lancet剛剛
內容摘要
This item is a 英语-language original; headline and summary shown as published.
Cardiovascular outcomes trials with GLP-1 receptor agonists, which to date have largely comprised peptide analogues of the incretin hormone GLP-1, have evolved…
本站僅提供標題與摘要索引，完整內容與版權均歸原發布方所有，請點擊原文連結閱讀。
前往原文- 所屬頻道
- 健康
- 所屬地區
- 英國
- 原文語種
- 英语
- 條目編號
- health-1d503d72
Comments 0 comments
No comments yet. Be the first.